Lifeline Biotechnologies, Inc. Featured on Stockbully.com
RENO, Nev.--(BUSINESS WIRE)--Lifeline Biotechnologies, Inc. (OTCPK:
LLBT), a developer of innovative medical technology, today announced that it is now featured on
www.stockbully.com. Stockbully.com gives attention to emerging growth companies that seek more exposure in the investment community.
Stockbully.com is a multimedia investor relations source that seeks out promising and mostly undiscovered companies in the market place and enables their clients to utilize multimedia marketing to gain exposure via the information highway.
“Lifeline Biotechnologies has a product, the First Warning System, which has the potential to revolutionize the medical industry, specifically in terms of early cancer detection,” said Adam Ben-Evi, President of Stockbully.com. “We are working with Lifeline to help increase awareness of the company, as well as its product, and Stockbully believes it can help attract the attention of new investors and possible consumer prospects.”
“We are pleased to have the expertise of www.Stockbully.com as a means to obtain additional exposure. I believe that this could be a very exciting year for our company and its shareholders and we look forward to sharing our success with the investment community,” stated Lifeline Biotechnologies, Inc. President and CEO Jim Holmes.
About Stockbully.com
Stockbully.com differentiates itself from traditional investor relations businesses, in that it strives to take a long-term approach. It nurtures and supports promising emerging companies with the aim of growing and appreciating in value. Through exposure on the Internet, Stockbully.com enables its clients to secure a place in their respective sector. Clients with limited financial means can utilize multimedia marketing via the Internet to gain a competitive edge. For more information, please visit http://www.stockbully.com/.
About Lifeline Biotechnologies, Inc:
Lifeline Biotechnologies, Inc. is an innovative medical technology company that is focused on completing the development of the First Warning System™, which was designed to assist in the early detection of breast cancer. Of the approximately $138 billion spent on cancer each year, Lifeline could potentially save the healthcare industry up to $4.1 billion annually, assuming the following are successfully completed: the development of the First Warning System™, the completion of clinical trials, and FDA pre-marketing clearance. Lifeline competes in the money markets for funds to support the development of its product. The cost of funds, for early stage companies like Lifeline, are expensive and the terms have been, and may continue to be, dilutive.
Safe Harbor: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.
